Free Trial
NASDAQ:PRFX

PainReform Q2 2026 Earnings Results & Report

PainReform logo
$0.69 -0.09 (-11.83%)
As of 02:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

PainReform reported Q2 2026 earnings on September 3, 2026. The company reported EPS of -$1.13, while revenue was $7 thousand.

Earnings Announcement Details

Quarter
Q2 2026
Time
Before Market Opens

PainReform EPS Results

Actual EPS
-$1.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PainReform Revenue Results

Actual Revenue
$7 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

PainReform Q2 2026 Earnings FAQ

PainReform (NASDAQ:PRFX) reported earnings of -$1.13 per share for Q2 2026. The report was announced on Thursday, September 3, 2026.

PainReform reported revenue of $7 thousand for Q2 2026.

PainReform Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More PainReform Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PainReform? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PainReform and other key companies, straight to your email.

About PainReform

PainReform (NASDAQ:PRFX) (NASDAQ: PRFX) is a clinical-stage specialty pharmaceutical company focused on developing treatments for acute post-operative pain. The company’s work is aimed at addressing pain experienced after surgical procedures and reducing reliance on conventional short-acting analgesics.

PainReform’s lead product candidate, PRF-110, is an extended-release formulation of ropivacaine, a local anesthetic. Designed for administration at the surgical site, PRF-110 is intended to provide prolonged pain relief during the days following surgery. The company has evaluated the product in clinical programs involving procedures such as bunionectomy and hernia repair.

Founded in Israel, PainReform has conducted its product development activities through clinical and regulatory programs targeting the U.S. market. As a development-stage company, its business remains centered on advancing PRF-110 and its drug-delivery technology rather than marketing an established portfolio of commercial products.

View PainReform Profile